#United States #San Francisco #Caresyntax #VectorMist #LASSO Protocol

Vector Sciences and Caresyntax: A New Era in Surgical Evidence

In an innovative partnership that promises to reshape surgical practices, Vector Science & Therapeutics Corp. has recently teamed up with Caresyntax, a leader in surgical intelligence and analytics. This collaboration aims to develop a comprehensive real-world evidence program for VectorMist™—a unique localized atomized drug delivery platform designed for laparoscopic procedures. This initiative signifies a major leap toward enhancing patient care by focusing on better pain management and minimizing reliance on opioids during recovery.

Dual Purpose of the Partnership

The partnership is strategically designed to fulfill a dual purpose. One is to implement The LASSO Protocol™, which stands for Laparoscopic Atomization System for Sparing Opioids, and the other is to establish a robust clinical evidence infrastructure that can inform future surgical advancements. By utilizing a network of affiliated surgical facilities, this program will collect data that encompasses crucial postoperative outcomes such as opioid utilization, length of hospital stay, and patient-reported pain scores.

Dr. Brad Worthington, Chief Medical Officer of Vector, emphasizes the significance of this initiative by stating, "Every surgical procedure should generate evidence that makes the next one better." He believes the data collected will not only build a trusted database but also guide continuous improvements in surgical methods.

Overview of the Real-World Evidence Program

The program will commence with the collection of baseline data reflecting current standard care procedures. Following this data gathering phase, the program will measure outcomes from procedures utilizing the VectorMist technology against the established baseline. This will culminate in the creation of a prospective comparative registry, which enables participating institutions to benchmark their outcomes in a standardized manner. It will provide valuable insights for hospitals and healthcare facilities aimed at improving patient care and outcomes.

The commitment of Caresyntax in designing and managing this multi-phase evidence program is key to its success. Their advanced analytics and workflow integration tools will aid healthcare providers in navigating the data landscape effectively, contributing to the goal of informed decision-making in surgical settings.

Beyond VectorMist

While the initial focus lies on the VectorMist platform, the partners are also exploring the potential for extending this evidence architecture to encompass Vector's wider portfolio, including its peptide therapeutics programs. By employing a shared methodology and data governance structure, they aim to facilitate a synergy that can streamline data collection efforts across multiple treatment lines, thus amplifying the impact of their combined technologies.

Caresyntax’s Chief Medical Informatics Officer, Dr. Bruce Ramshaw, noted that this partnership showcases how modern medtech companies should operate. He states, "Vector is doing what the next generation of medtech companies must do — building the evidence engine alongside the product."

Both companies plan to leverage the findings from this research initiative for educational purposes, including a white paper series aimed at establishing opioid-sparing methodologies as an essential clinical practice category.

Conclusion

This partnership between Vector Science & Therapeutics and Caresyntax is paving the way for data-driven improvements in surgical practices. By creating a solid foundation for comparative analysis and evidence collection, they are not only enhancing the way medications are delivered during surgery but also positioning themselves as frontrunners in the evolution of surgical care. As they embark on this ambitious journey, one thing is clear: they are setting new standards for accountability in surgical outcomes and striving to ensure that every surgical intervention is supported by substantive evidence.

Vector Science & Therapeutics, headquartered in Mequon, Wisconsin, focuses on innovative drug delivery technologies, while Caresyntax is renowned for its regulatory-grade analytics that enhances surgical performance worldwide. Together, they are redefining what it means to deliver evidence-based surgical care.